+62%

est. 2Y upside i

HealthcareSeries D+

Rank

#803

Sector

Healthcare AI / HealthTech

Est. Liquidity

~4Y

Data Quality

Data: Low

Suki offers a high-risk, high-potential equity opportunity.

Last updated: July 19, 2026

Bull (20%)+345%

Strong growth continues; multiple holds at 16.7x due to category leadership and potential IPO, driving exit value $2.66B.

Base (40%)+73%

Revenue grows to $159M; multiple compresses to 6x in line with public comps, yielding $954M exit valuation net of 20% dilution.

Bear (40%)-89%

Growth slows; multiple drops to 2x; preference stack absorbs $165M, common recovers only $153M before dilution penalty.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

33%

Total funding of $165M at a $500M valuation gives preferred a 33% overhang, severely diluting common in downside.

Dilution Risk

high

Given high burn rate and 18+ months since last round, a new raise is likely within 12-18 months, adding 15-25% dilution.

Secondary Liquidity

none

No secondary market activity detected; likely no liquidity for employees pre-exit.

View all 26 open roles at Suki →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Suki's data — designed to show you've done your homework.

  • 1

    “How does Suki's product differentiation hold up against Nuance's Dragon Medical and Epic's native tools?”

  • 2

    “What is the unit economics and path to profitability?”

  • 3

    “What is the expected timeline for liquidity events and how does the equity structure treat employees?”

Community

Valuation Sentiment

Our model estimates +62% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.